Detail

Study ID: NRG GY005

Title:

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Location:
Bemidji Clinic, Fargo Region, Sioux Falls Region
Principal Investigator:
Maria Bell, MD
Disease:
Ovary/Fallopian Tube/Primary Peritoneal
Stage:
Phase II/III
Status:
Active - Open to Accrual